Non Small Cell Lung Cancer, Small-cell Lung Cancer
Conditions
Brief summary
This is a Phase 1b, multicenter, 2-part study of ALRN-6924 for the prevention of chemotherapy-induced side effects. Part 1 SCLC is an open-label, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side effects in patients with p53-mutated ED SCLC undergoing 2nd-line treatment with topotecan. (Part 1 has completed enrollment). Part 2 NSCLC is a randomized, double-blind, placebo-controlled, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side effects in patients with p53-mutated advanced NSCLC of adenocarcinoma histology receiving 1st-line treatment with carboplatin plus pemetrexed with or without immunotherapy.
Detailed description
During Part 1 SCLC, topotecan will be administered per standard practice on Days 1-5 of 21-day cycles. Patients will be randomized to receive 1 of 2 initial ALRN-6924 dose levels, to be administered prior to each planned topotecan dose. The incidence, severity and duration of hematologic toxicities, including neutropenia, thrombocytopenia, and febrile neutropenia, will be determined. The safety and tolerability of each ALRN-6924 dose level will be assessed during Part 1. ALRN-6924 is given either 24 hr or 6 hr prior to each topotecan administration. Part 2 NSCLC of the study will be conducted in two stages. In Stage 1, a total of 20 patients will be randomized 1:1 to receive (with or without immunotherapy) either carboplatin plus pemetrexed plus ALRN-6924 or carboplatin plus pemetrexed plus placebo. During Stage 1 of Part 2 NSCLC, two interim analyses will be conducted after 10 and 20 patients, respectively, have been evaluated. The purpose of the two interim analyses is to confirm safety and exclude futility. In Stage 2 of Part 2 NSCLC, an additional 40 patients will be randomized to treatment as described for Stage 1. Immunotherapy and/or bevacizumab may be used concurrently with chemotherapy and after completion of 1st-line treatment (i.e., for maintenance purposes) as per local standard of care. Time of administration of immunotherapy and/or bevacizumab relative to chemotherapy will follow local standards of care.
Interventions
DRUGALRN-6924
ALRN-6924 administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
DRUGCarboplatin
Carboplatin administered IV on Day 1 of every 21-day cycle.
DRUGPemetrexed
Pemetrexed administered IV on Day 1 of every 21-day cycle.
DRUGPlacebo
Placebo administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
DRUGTopotecan
Topotecan administered IV on Days 1-5 of every 21-day cycle.
Sponsors
Aileron Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Phase 1b, Part 2 NSCLC Inclusion Criteria: * Histopathological confirmation of Stage IV NSCLC of adenocarcinoma histology. Cytological diagnosis of NSCLC is acceptable if sufficient tumor tissue is available for p53 mutation analysis. FDA approved liquid biopsies are also acceptable. * Presence of one or more p53 mutations. * Measurable disease using RECIST 1.1. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. * Adequate hematological status. * Adequate hepatic and renal function. Phase 1b, Part 2 NSCLC
Exclusion criteria
* Advanced NSCLC tumors with EGFR mutations or ALK re-arrangement or other actionable genetic aberrations for which an approved targeted treatment is available. Patients who received prior treatment with EGFR or ALK inhibitors or other systemic drugs or immunotherapy for NSCLC are not eligible. * Patients who are candidates for anti-PD-1 monotherapy in 1st line advanced NSCLC (e.g. tumors with high PD-L1 expression). * Presence of active central nervous system metastases and/or carcinomatous meningitis. * Significant weight loss (≥15% body weight) within the 4 weeks prior to enrollment. Phase 1b, Part 1 SCLC Inclusion Criteria: * Histopathological confirmation of ED SCLC that has recurred or been refractory to one line of treatment with standard platinum-based chemotherapy or immuno-chemotherapy. Patients who received immunotherapy after platinum-based chemotherapy are eligible. * Presence of one or more p53 mutations. * Measurable disease using RECIST 1.1. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2. * Adequate hematological status. * Adequate hepatic and renal function. Phase 1b, Part 1 SCLC
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1b Part 2 NSCLC | Approximately 6 months | Proportion of completed treatment cycles that are free of Grade ≥ 3 hematological toxicities (including neutropenia, anemia, thrombocytopenia and febrile neutropenia), and free of chemotherapy dose reductions, and free of use of growth factors and transfusions. |
| Phase 1b Part 1 SCLC | Approximately 19 months | Proportion of patients with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 3/4 treatment emergent adverse events (TEAEs) |
Countries
Bosnia and Herzegovina, Germany, Italy, Poland, Serbia, Spain, United States
Outcome results
None listed